BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

Journal of Neurology

Volumn 258, Issue 3, 2011, Pages 449-456

  MacManus, D G ^a   Miller, D H ^a   Kappos, L ^c   Gold, R ^d   Havrdova, E ^e   Limmroth, V ^f   Polman, C H ^g   Schmierer, K ^a,b   Yousry, T A ^a   Eraksoy, M ^h   Meluzinova, E ⁱ   Dufek, M ^j   Yang, M ^k   O'Neill, G N ^k   Dawson, K ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d ST JOSEF HOSPITAL   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF COLOGNE   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j MASARYK UNIVERSITY   (Czech Republic)

^k BIOGEN   (United States)

more..

Author keywords

BG 12; Clinical trial; Dimethyl fumarate; Hypointense lesions; MRI; Multiple sclerosis

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; PLACEBO;

ADULT; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79953769528     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5777-z     Document Type: Article

References (26)

1. Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145:101-107 (Pubitemid 43893938)
2. Wierinckx A, Brevé J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM (2005) Detoxification enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 166:132-143 (Pubitemid 41074663)
3. Lukashev M, Zeng W, Goelz S, Lee D, Linker R, Gold R et al (2007) Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities [abstract]. Mult Scler 13(suppl 2):S149
4. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y et al (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322 (Pubitemid 27373291)
5. Venugopal R, Jaiswal AK (1998) Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17:3145-3156 (Pubitemid 29020810)
6. Chen XL, Dodd G, Thomas S et al (2006) Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 290:H1862-H1870
7. Hubbs AF, Benkovic A, Miller DB, O'Callaghan JP, Battelli L, Schwegler-Berry D et al (2007) Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 170:2068-2076 (Pubitemid 47339279)
8. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V et al (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463-1472
9. van Waesberghe JH, van Walderveen MA, Castelijns JA, Scheltens P, Lycklama à Nijeholt GJ, Polman CH et al (1998) Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 19:675-683
10. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783-793 (Pubitemid 27481551)
11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121-127
12. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
13. Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, European Study Group on Interferon beta-1b in secondary progressive MS et al (2001) The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 57:2185-2190 (Pubitemid 34016449)
14. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M et al (2004) Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 251:407-413 (Pubitemid 38501297)
15. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF et al (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34:661-669 (Pubitemid 23333237)
16. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56:407-415 (Pubitemid 39166560)
17. van Walderveen MAA, Lycklama à Nijeholt GJ, Adèr J, Jongen PJ, Polman CH, Castelijns JA et al (2001) Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 58:76-81
18. van Walderveen MAA, Barkhof F, Pouwels PJW, van Schijndel RA, Polman CH, Castelijns JA et al (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46:79-87 (Pubitemid 29314385)
19. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G, European/Canadian Glatiramer Acetate Study Group (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733
20. Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD (2009) New acute and chronic black holes in patients with multiple sclerosis randomized to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry 80:1337-1343
21. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M et al (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13:604-610 (Pubitemid 43873632)
22. Vargas MR, Pehar M, Cassina P, Martínez-Palma L, Thompson JA, Beckman JS et al (2005) Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal chord astrocytes. J Biol Chem 280:25571-25579 (Pubitemid 40962264)
23. Li J, Johnson D, Calkins M, Wright L, Svendsen C, Johnson J (2005) Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83:313-328 (Pubitemid 40227901)
24. Satoh T, Okamato S-I, Cui J, Watanabe Y, Furuta K, Suzuki M et al (2006) Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic [sic] phase II inducers. Proc Natl Acad Sci USA 103:768-773 (Pubitemid 43153100)
25. Zhao J, Moore AN, Redell JB, Dash PK (2007) Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury. J Neurosci 27:10240-10248 (Pubitemid 47450456)
26. Van den Elskamp I, Lembcke J, Dattola V, Beckmann K, Pohl C, Hong W et al (2008) Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 14:764-769